Series B Round

YolTech Therapeutics is a pioneering gene editing company dedicated to developing robust gene editing medicines to treat patients with serious diseases. The company specializes in next-generation in vivo gene-editing therapies designed for one-time treatment, utilizing novel CRISPR-Cas enzymes and innovative lipid formulations. This funding round will support the advancement of their lead product candidate, YOLT-203, which has recently received Orphan Drug Designation. The funds will be used to accelerate clinical trials and expand the company's research capabilities in gene editing technologies. This financing round was led by AstraZeneca and CICC, highlighting the growing interest and investment in innovative gene editing solutions. The investment will also facilitate partnerships with research institutions to enhance the development pipeline. The Series B round reflects the increasing momentum in the gene editing sector, with a focus on addressing unmet medical needs.